IAC’s Honor Roll for Mandatory Influenza Vaccination of Healthcare Personnel climbs to nearly 600 enrollees.
Major professional societies support mandatory vaccination.

In October 2009, the Immunization Action Coalition (IAC) launched the “Honor Roll for Mandatory Influenza Vaccination of Healthcare Personnel” at www.immunize.org/honor-roll/influenza-mandates. This was one of the earliest efforts to promote mandatory influenza vaccination of healthcare staff. Since that time, many national healthcare organizations have established position statements supporting mandatory influenza vaccination of healthcare personnel. These organizations include:

- American Academy of Family Physicians
- American Academy of Pediatrics
- American College of Physicians
- American Hospital Association
- American Medical Directors Association
- American Pharmacists Association
- American Public Health Association
- Association for Professionals in Infection Control and Epidemiology
- Infectious Diseases Society of America

- National Association of County and City Health Officials
- National Business Group on Health
- National Patient Safety Foundation
- Pediatric Infectious Diseases Society of America
- Society for Healthcare Epidemiology

Details about the position statements of these organizations can be found in the summary article titled “FirstDoNoHarm: Mandatory Influenza Vaccination Policies for Healthcare Personnel Help Protect Patients,” which is featured on page 9 of this issue of Vaccinate Adults. The position statements are also available on IAC’s website at www.immunize.org/honor-roll/influenza-mandates.

IAC would like to recognize some of the earliest members of the honor roll, along with the Infectious Diseases Society of America (IDSA), which was the first professional society to issue such a policy statement. Hospitals and healthcare systems that were honored at the launch include Barnes Jewish Corporation (BJC) Healthcare, Missouri; Children’s Hospital of Philadelphia; Creighton University; Hospital of the University of Pennsylvania; Loyola University Health System, Illinois; MedStar Health, Maryland and Washington, DC; TriHealth, Good Samaritan and Bethesda North Hospitals, Cincinnati, Ohio; University of Iowa Hospitals; and Virginia Mason Medical Center, Seattle.

At this time, nearly 600 healthcare systems, hospitals, and medical practices have met all of the requirements to be honored. A complete list of members of the honor roll is available online at www.immunize.org/honor-roll/influenza-mandates/honorees.asp.

Please Apply for the Honor Roll

If your organization requires influenza vaccination for its healthcare personnel but is not yet on the honor roll, please apply. To be added, your healthcare system must (1) require influenza vaccination for all staff and (2) include strong measures (e.g., a mask requirement, reassignment to non-patient care, or dismissal) to prevent transmission of influenza to patients from staff who do not get vaccinated.

The honor roll application form is available online at www.immunize.org/honor-roll/influenza-mandates/apply.aspx.

Find out more about IAC’s Honor Roll for Mandatory Influenza Vaccination of Healthcare Personnel at www.immunize.org/honor-roll/influenza-mandates.

What’s In This Issue

IAC’s Honor Roll for Mandatory Vaccination of Healthcare Personnel climbs................. 1
Ask the Experts:
CDC Answers Your Questions......................... 1
Influenza Vaccine Products for 2015–2016........ 5
Screening Checklists for Contraindications to Influenza Vaccines.................. 6
Standing Orders Template for Influenza Vaccine.......................... 7
How to Administer Influenza Vaccines........... 8
First Do No Harm: Mandatory HCP Influenza Vaccination Policies........ 9
Influenza Education Materials from IAC........... 10
Pneumococcal Vaccination Recommendations for Adults and Children........ 11
Standing Orders Template for Pneumococcal Vaccines.................... 12
Take a Stand! Register for IAC’s Standing Orders Workshops.................. 13
It’s Federal Law!
You Must Use VISs with Adults....................... 14
Products Available for Purchase from IAC......... 15
IAC’s Immunization Resources Order Form........ 16

Ask the Experts

The Immunization Action Coalition extends thanks to our experts, medical officer Andrew T. Kroger, MD, MPH, and nurse educator Donna L. Weaver, RN, MN, both with the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC).

Influenza vaccines

Which influenza vaccines are available for this influenza season?
Multiple manufacturers are producing influenza vaccine for the U.S. market for the 2015–2016 season. Inactivated, recombinant (inactivated), and live attenuated vaccines are being produced using egg-based, cell culture-based, and recombinant technologies. The live attenuated vaccine and some of the inactivated influenza vaccines are quadrivalent (contain four strains of influenza virus) rather than trivalent (three strains). You can find information on all influenza vaccines available in the U.S. for the current season and the age groups approved by FDA by going to the Immunization Action Coalition’s (IAC) information sheet titled “Influenza Vaccine Products for the 2015–2016 Influenza Season” available at www.immunize.org/catg.d/p4072.pdf.

Immunization questions?

► Email nipinfo@cdc.gov
► Call your state health department (phone numbers at www.immunize.org/coordinators)
Ask the Experts…continued from page 1

Is it acceptable to administer a dose of the quadrivalent influenza vaccine to a patient who has already received the trivalent vaccine?

No. CDC’s Advisory Committee on Immunization Practices (ACIP) does not recommend more than 1 dose of influenza vaccine in a season (except for certain children age 6 months through 8 years for whom 2 doses are recommended).

How late in the season can I vaccinate my patients with influenza vaccine?

Peak influenza activity generally occurs in January or February. Providers should continue vaccinating patients throughout the influenza season, including into the spring months (for example, through May), as long as they have unexpired vaccine in stock and unvaccinated patients in their office.

Because influenza occurs in many areas of the world during April through September, vaccine should be given to travelers who missed vaccination in the preceding fall and winter. Vaccine can be given through the month of June since most injectable influenza vaccine has a June 30 expiration date.

If an unvaccinated patient who has just recovered from a diagnosed case of influenza comes into our office, should we vaccinate this patient?

Yes. Influenza vaccine contains three or four influenza virus strains; two A viruses and one or two B viruses, which are prepared based on circulating viruses from the previous influenza season. Infection from one virus type does not confer immunity to other types and a person could be exposed to more than one type during a typical influenza season, so a person who has recently had influenza will benefit from receipt of a vaccine that contains additional influenza virus strains.

A study published in 2014 found that the injectable vaccine Fluzone High-Dose (Sanofi) protects people 65 years and older better than standard-dose Fluzone. Does ACIP preferentially recommend use of Fluzone High-Dose for all people age 65 years and older?

Asthma is a precaution for the live attenuated influenza vaccine. However, despite published evidence of better protection from Fluzone High-Dose when compared to standard-dose Fluzone (N Engl J Med 2014; 371:635–45), ACIP has not stated a preference for this vaccine for people age 65 years and older.

May I give Fluzone High-Dose to patients younger than age 65 years?

No. Fluzone High-Dose is licensed only for people age 65 years and older and is not recommended for younger people.

Sometimes patients age 65 years and older who have received the standard-dose influenza vaccine hear about Fluzone High-Dose and want to receive that, too. Is this okay to administer?

No. ACIP does not recommend that anyone receive more than 1 dose of influenza vaccine in a season (except for certain children age 6 months through 8 years for whom 2 doses are recommended).

Would giving an older patient 2 doses of standard-dose influenza vaccine be the same as administering the high-dose product?

No, and this is not recommended.

Is the nasal spray influenza vaccine, FluMist, contraindicated for adults with asthma?

Asthma is a precaution for the live attenuated influenza vaccine (LAIV, FluMist, MedImmune) in people 5 years of age and older.

Ask the Experts…continued on page 3

IAC’s “Ask the Experts” team from the Centers for Disease Control and Prevention

Andrew T. Kroger, MD, MPH
Donna L. Weaver, RN, MN

Disclaimer: Vaccinate Adults! is available to all readers free of charge. Some of the information in this issue is supplied to us by the Centers for Disease Control and Prevention in Atlanta, Georgia, and some information is supplied by third-party sources. The Immunization Action Coalition (IAC) has used its best efforts to accurately publish all of this information, but IAC cannot guarantee that the original information as supplied by others is correct or complete, or that it has been accurately published. Some of the information in this issue is created or compiled by IAC. All of the information in this issue is a time-critical nature, and we cannot guarantee that some of the information is not now outdated, inaccurate, or incomplete. IAC cannot guarantee that reliance on the information in this issue will cause no injury. Before you rely on the information in this issue, you should first independently verify its current accuracy and completeness. IAC is not licensed to practice medicine or pharmacology, and the providing of the information in this issue does not constitute such practice. Any claim against IAC must be submitted to binding arbitration under the auspices of the American Arbitration Association in St. Paul, Minnesota.
Ask the Experts…continued from page 2

What is the preferred anatomic site for administration of inactivated influenza vaccine (IIV)?

With the exception of intradermal vaccine (Fluzone Intradermal, Sanofi), IIV should be administered in the deltoid muscle of an older child, adolescent, or adult. The anterolateral thigh muscle can also be used if necessary. It is critical that intramuscular influenza vaccine be injected into a muscle. Influenza vaccination season is an opportune time to review proper intramuscular injection techniques with your staff. IAC has prepared a handout on how to administer intramuscular vaccine injections (available at www.immunize.org/catg.d/p2020.pdf) that can be used as a staff training tool.

We offer healthcare professionals live attenuated influenza vaccine (LAIV) but question whether newborn intensive care unit (NICU) staff can receive this vaccine without compromising neonates. Neonates in an NICU are not considered severely immunocompromised. NICU personnel may receive LAIV if otherwise eligible (younger than 50 years, healthy, and not pregnant).

Should staff at drive-through influenza vaccination clinics encourage drivers to park and wait for 15 minutes after vaccination to make sure they don’t have a vaccination reaction or syncopal (fainting) episode?

Yes. Syncope has been reported following vaccination. It is prudent for all persons to be observed for syncope for at least 15 minutes after vaccination.

Some of our patients believe that they have had reactions to influenza vaccine in the past, and request the dose to be split into 2 doses administered on different days. Is this an acceptable practice?

This is definitely not an acceptable practice. Doses of influenza vaccine (or any other vaccine) should never be split into “half doses.” If a “half dose” is given, it should not be accepted as a valid dose and should be repeated as soon as possible with a full age-appropriate dose.

The pneumococcal conjugate vaccine (PCV13, Pneumovax 23, Prevnar, Pfizer) package insert says that in adults, antibody responses to PCV13 were diminished when given with inactivated influenza vaccine. Does this mean we should not give PCV13 and influenza vaccine at the same visit?

The available data have been interpreted that any changes in antibody response to either of the vaccines’ components were clinically insignificant. If PCV13 and influenza vaccine are both indicated and recommended they should be administered at the same visit. See the PCV13 ACIP recommendations at www.cdc.gov/mmwr/pdf/ww/mm6337.pdf, page 824.

Do statin medications (taken to lower blood lipid levels) affect the efficacy of influenza vaccine?

Two recent studies raise the possibility that statin medications may blunt the effectiveness of influenza vaccine in seniors. Experts caution that more research is needed to better understand the issue. Because of their benefit, seniors should not stop taking their statin without consultation with their health care provider. Influenza vaccine remains the best protection we have against influenza, and provides at least some protection in people who take statins, so patients should still receive an influenza vaccine to be protected. There is no change to the ACIP recommendation for influenza vaccine.

Pneumococcal vaccines

Do patients who were vaccinated with 1 or 2 doses of PPSV23 before age 65 need an additional dose of PPSV23 at age 65?

Yes. Patients who received 1 or 2 doses of PPSV23 for any indication at age 64 years or younger should receive an additional dose of PPSV23 vaccine at age 65 years or older if at least 5 years have elapsed since their previous PPSV23 dose. Patients age 65 years and older who have not already received a dose of pneumococcal conjugate vaccine (PCV13) will need this as well. PCV13 is routinely recommended at age 65 and PPSV23 is administered one year later.

Should a healthy 75-year-old patient who was given PPSV23 at age 65 years be revaccinated?

No. Adults who were first vaccinated at age 65 years or older do not require revaccination. Make sure they have also received a dose of PCV13, which is routinely recommended at age 65 years.

Can we administer PCV13 and PPSV23 to a person 65 years of age or older at the same visit? If not, what is the recommended interval between doses?

PCV13 and PPSV23 should not be given at the same visit. Healthy people 65 years of age and older should receive PCV13 first, followed by a dose of PPSV23 one year later. If the patient has a high-risk medical condition (such as immunocompromised or asplenia) the first PPSV23 dose can follow the PCV13 dose by 8 weeks.

Stay current with FREE subscriptions

The Immunization Action Coalition’s 2 periodicals, VaccineE News and Needle Tips, and our email news service, IAC Express, are packed with up-to-date information.

Subscribe to all 3 free publications in one place. It’s simple! Go to www.immunize.org/subscribe
Rather than giving PCV13 first and waiting 8 weeks to give PPSV23 as recommended for an immunocompromised adult patient, we inadvertently gave both vaccines at the same visit. We are looking for guidance. Although PCV13 and PPSV23 should not be administered at the same visit, CDC does not recommend repeating either vaccine dose should this occur. You should inform the patient of the error and let them know that they will not need to repeat either dose.

What is the recommended interval between doses for adult patients who have already received 1 dose of PPSV23 and now need PCV13?

For patients who have already had one or more doses of PPSV23, it is recommended to wait at least a year after PPSV23 before administering PCV13. If the patient is recommended to receive a second dose of PPSV23, delay that second PPSV23 dose at least 8 weeks following PCV13 and 5 years or more following the first dose of PPSV23.

If patients who are in a recommended risk group for PPSV23 or PCV13 aren’t sure if they have previously received these vaccines, should health care providers vaccinate them?

If patients do not have a documented vaccination history for these two vaccines and their records are not readily obtainable, you should administer the recommended doses. Extra doses will not cause harm to the patient.

If influenza vaccine is recommended for healthcare workers to protect high-risk patients from getting influenza, why aren’t pneumococcal vaccines also recommended?

Influenza virus is easily spread from healthcare workers to their patients, and infection usually leads to clinical illness. Pneumococcus is probably not spread from healthcare workers to their patients as easily as is influenza, and infection with pneumococcus does not necessarily lead to clinical illness. Host factors (such as age and underlying illness) are more important in the development of invasive pneumococcal disease than nasopharyngeal colonization with the organism. When you’re giving influenza vaccine to your patients in the fall, don’t forget to assess their need for pneumococcal vaccines as well as all other vaccines, including Tdap and zoster.